# Hoffmann-La Roche: Phase 3 study closed enrollment, 122 enrolled (NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis |
| NCT ID | NCT05503264 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | NMDAR Autoimmune Encephalitis; LGI1 Autoimmune Encephalitis |
| Intervention types | drug, other |
| Target enrollment | 122 |
| Site countries | United States, Argentina, Brazil, China, Czechia, Denmark, France, Ghana, Israel, Italy, Japan, Netherlands |
| Posted | 2022-08-16 |
| Planned start | 2022-09-27 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-08 |
| Last update posted | 2026-10-08 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 122 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05503264). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.